This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
by Zacks Equity Research
CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
by Zacks Equity Research
Viridian Therapeutics (VRDN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Sell Stocks for April 22nd
by Zacks Equity Research
BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022
3D Systems (DDD) Joins CollPlant for Bioprinted Breast Tissue Matrix
by Zacks Equity Research
The collaborative efforts of 3D Systems (DDD) and CollPlant aim to eliminate the odds of adverse immune response in the human body induced by procedures using tissue derived from humans and animals.
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $14.68 in the latest trading session, marking a +1.91% move from the prior day.
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Stock Moves -0.22%: What You Should Know
by Zacks Equity Research
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.77 in the latest trading session, marking a -0.22% move from the prior day.
CollPlant (CLGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
CollPlant (CLGN) is set to report earnings and revenues, and provide product updates when it releases first-quarter 2021 results.
Is CollPlant Biotechnologies Ltd. Sponsored (CLGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLGN) Outperforming Other Medical Stocks This Year?
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.
Has CollPlant Biotechnologies Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLGN) Outperforming Other Medical Stocks This Year?
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.33, marking a +1.76% move from the previous day.
The Zacks Analyst Blog Highlights: Cirrus Logic, HighPoint Resources Corp, Immersion Corp, CollPlant Biotechnologies and Suburban Propane Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cirrus Logic, HighPoint Resources Corp, Immersion Corp, CollPlant Biotechnologies and Suburban Propane Partners
6 Beaten Down Stocks with Solid Growth Potential
by Sejuti Banerjea
Are you going to sit around to try and price a bottom or are you going to grab stocks that look obviously cheap today?
USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has CollPlant Holdings Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLGN) Outperforming Other Medical Stocks This Year?
Is CollPlant Holdings Ltd. Sponsored (CLGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLGN) Outperforming Other Medical Stocks This Year?
What Makes CollPlant Holdings Ltd. Sponsored ADR (CLGN) a New Strong Buy Stock
by Zacks Equity Research
CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CollPlant's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.
Has CollPlant Holdings Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CLGN) Outperforming Other Medical Stocks This Year?
3D Systems Joins CollPlant in Regenerative Medicine Efforts
by Zacks Equity Research
3D Systems (DDD) and CollPlant aim to create state-of-the-art 3D bioprinters and BioInks to produce tissues and scaffolds.
CollPlant Holdings Ltd. Sponsored ADR (CLGN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for October 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 11th.